F Esposito1,2, L Ferrè3,4, F Clarelli4, M A Rocca3,5, G Sferruzza3,4, L Storelli5, M Radaelli3, F Sangalli3, L Moiola3, B Colombo3, F Martinelli Boneschi3,4, G Comi3,4, M Filippi3,5, V Martinelli3. 1. Department of Neurology, San Raffaele Scientific Institute, Via Olgettina, 48, 20132, Milan, Italy. esposito.federica@hsr.it. 2. Laboratory of Human Genetics of Neurological Disorders, CNS Inflammatory Unit and INSPE, San Raffaele Scientific Institute, Milan, Italy. esposito.federica@hsr.it. 3. Department of Neurology, San Raffaele Scientific Institute, Via Olgettina, 48, 20132, Milan, Italy. 4. Laboratory of Human Genetics of Neurological Disorders, CNS Inflammatory Unit and INSPE, San Raffaele Scientific Institute, Milan, Italy. 5. Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute San Raffaele University, Milan, Italy.
Abstract
BACKGROUND: Treatment choice in multiple sclerosis (MS) is crucial for optimizing risk-benefit profile. OBJECTIVE: To assess fingolimod (FTY) effectiveness and identify baseline features associated to disease activity in a large Italian cohort of Relapsing-Remitting (RR) MS patients. METHODS: Three-hundred sixty-seven RRMS patients starting FTY treatment at San Raffaele Hospital (Milan-Italy) underwent clinical and MRI evaluations for 2 years. Treatment response was assessed considering the proportion of patients with no evidence of disease activity (NEDA) and recording the time to first relapse. Primary analyses were performed stratifying for Natalizumab (NTZ) treatment in the year before (NO_NTZ vs NTZ group), to account for post-NTZ reactivation. RESULTS: Almost half of patients were NEDA after 2 years, 53.4% in the NO_NTZ group and 36.2% in the NTZ group. Despite an opposite trend during the first 6-12 months, at 2-year follow-up the two groups were comparable for relapses and number of new/enlarging T2 and Gd-enhancing lesions. Baseline parameters of higher disease activity (ARR, Gd enhancing lesions and age at onset) were associated with increased likelihood of failing NEDA criteria or with shorter time to relapse (p < 0.05). CONCLUSIONS: Our data strengthen FTY effectiveness in everyday clinical practice, even in patients switching from NTZ treatment. Baseline parameters of inflammatory activity are the most important prognostic factors for mid-term disease reactivation also during second-line treatment with FTY, providing hints on how to select therapies towards a more personalized management.
BACKGROUND: Treatment choice in multiple sclerosis (MS) is crucial for optimizing risk-benefit profile. OBJECTIVE: To assess fingolimod (FTY) effectiveness and identify baseline features associated to disease activity in a large Italian cohort of Relapsing-Remitting (RR) MSpatients. METHODS: Three-hundred sixty-seven RRMS patients starting FTY treatment at San Raffaele Hospital (Milan-Italy) underwent clinical and MRI evaluations for 2 years. Treatment response was assessed considering the proportion of patients with no evidence of disease activity (NEDA) and recording the time to first relapse. Primary analyses were performed stratifying for Natalizumab (NTZ) treatment in the year before (NO_NTZ vs NTZ group), to account for post-NTZ reactivation. RESULTS: Almost half of patients were NEDA after 2 years, 53.4% in the NO_NTZ group and 36.2% in the NTZ group. Despite an opposite trend during the first 6-12 months, at 2-year follow-up the two groups were comparable for relapses and number of new/enlarging T2 and Gd-enhancing lesions. Baseline parameters of higher disease activity (ARR, Gd enhancing lesions and age at onset) were associated with increased likelihood of failing NEDA criteria or with shorter time to relapse (p < 0.05). CONCLUSIONS: Our data strengthen FTY effectiveness in everyday clinical practice, even in patients switching from NTZ treatment. Baseline parameters of inflammatory activity are the most important prognostic factors for mid-term disease reactivation also during second-line treatment with FTY, providing hints on how to select therapies towards a more personalized management.
Authors: M P Sormani; J Rio; M Tintorè; A Signori; D Li; P Cornelisse; B Stubinski; M l Stromillo; X Montalban; N De Stefano Journal: Mult Scler Date: 2012-09-25 Impact factor: 6.312
Authors: Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin Journal: N Engl J Med Date: 2010-01-20 Impact factor: 91.245
Authors: Peter Alping; Thomas Frisell; Lenka Novakova; Protik Islam-Jakobsson; Jonatan Salzer; Anna Björck; Markus Axelsson; Clas Malmeström; Katharina Fink; Jan Lycke; Anders Svenningsson; Fredrik Piehl Journal: Ann Neurol Date: 2016-04-20 Impact factor: 10.422
Authors: J Río; J Castilló; A Rovira; M Tintoré; J Sastre-Garriga; A Horga; C Nos; M Comabella; X Aymerich; X Montalbán Journal: Mult Scler Date: 2009-07 Impact factor: 6.312
Authors: Chris H Polman; Stephen C Reingold; Brenda Banwell; Michel Clanet; Jeffrey A Cohen; Massimo Filippi; Kazuo Fujihara; Eva Havrdova; Michael Hutchinson; Ludwig Kappos; Fred D Lublin; Xavier Montalban; Paul O'Connor; Magnhild Sandberg-Wollheim; Alan J Thompson; Emmanuelle Waubant; Brian Weinshenker; Jerry S Wolinsky Journal: Ann Neurol Date: 2011-02 Impact factor: 10.422
Authors: María José Zarzuelo Romero; Cristina Pérez Ramírez; María Isabel Carrasco Campos; Almudena Sánchez Martín; Miguel Ángel Calleja Hernández; María Carmen Ramírez Tortosa; Alberto Jiménez Morales Journal: J Pers Med Date: 2021-04-23
Authors: G Sferruzza; F Clarelli; E Mascia; L Ferrè; L Ottoboni; M Sorosina; S Santoro; L Moiola; V Martinelli; G Comi; F Martinelli Boneschi; M Filippi; P Provero; Federica Esposito Journal: Mol Neurobiol Date: 2021-06-28 Impact factor: 5.590
Authors: Francisco Barrero; Javier Mallada-Frechin; María Luisa Martínez-Ginés; María Eugenia Marzo; Virginia Meca-Lallana; Guillermo Izquierdo; José Ramón Ara; Celia Oreja-Guevara; José Meca-Lallana; Lucía Forero; Irene Sánchez-Vera; María José Moreno Journal: PLoS One Date: 2020-04-02 Impact factor: 3.240